IPO - SERA PROGNOSTICS, INC.

Form Type: 8-K

Filing Date: 2025-02-12

Corporate Action: Ipo

Type: New

Accession Number: 000119312525024518

Filing Summary: On February 10, 2025, Sera Prognostics, Inc. entered into an underwriting agreement for an underwritten public offering of 1,250,000 shares of Class A common stock at a price of $4.00 per share, along with pre-funded warrants for 11,250,000 shares at a price of $3.9999 per warrant. The total gross proceeds from the offering are expected to be approximately $50 million. The agreement with underwriters includes an option to purchase an additional 1,875,000 shares within 30 days. The closing of the offering is expected on or about February 12, 2025, pending customary closing conditions. Proceeds will be used to enhance commercial infrastructure, prepare for market expansion in the EU, support studies for the PreTRM test, and for general corporate purposes. The shares and warrants will be issued under a shelf registration statement filed with the SEC. Press releases regarding the launch and pricing of the offering were issued by the company on the same day.

Form Type: 424B5

Filing Date: 2025-02-10

Corporate Action: Ipo

Type: New

Accession Number: 000119312525023601

Filing Summary: On February 10, 2025, Sera Prognostics, Inc. filed a preliminary prospectus supplement related to an initial public offering (IPO) of shares of its Class A common stock and pre-funded warrants. This offering is part of a shelf registration that allows the company to sell securities with an aggregate offering price of up to $100 million. The Class A common stock will be sold at a public offering price, with a special note on the pricing structure for pre-funded warrants, which will be offered in lieu of shares to certain investors. The document highlights Sera's proprietary focus on improving maternal and neonatal health through advanced biomarker tests, particularly through their signature product, the PreTRM test, aimed at predicting the risk of preterm birth. Recent developments in their PRIME study have indicated significant reductions in neonatal morbidity rates among low-risk patients, promising a positive impact on maternal health outcomes once the product is further commercialized. This prospectus emphasizes the associated risks of investment, potential use of proceeds, and ongoing corporate structures of Sera.